Big Pharma Eyes Strategic Acquisitions in 2025 to Counter Patent Expirations

Economy

1 year ago

News sources:

Credited from: BUSINESSINSIDER

Big Pharma is set to ramp up **acquisitions in 2025** as key drugs face patent expirations, notably **Merck's Keytruda** and **Pfizer's Eliquis**.
The loss of exclusivity for these drugs is expected to prompt significant revenue declines, with **Keytruda** generating **$25 billion** in 2023 alone.
**Chris Roop**, an M&A expert, predicts increased activity in the biopharma sector, especially in emerging markets like **obesity** and **oncology**.
Obesity is anticipated to become a **$100 billion to $150 billion market**, driving companies to seek new treatments in this lucrative area.
Major pharmaceutical firms are also eyeing advancements in **precision oncology** and **cardiovascular drugs**, indicating a broad strategy for future growth.

For more details, visit the original article here.